563 related articles for article (PubMed ID: 34373860)
1. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals.
Maeda K; Amano M; Uemura Y; Tsuchiya K; Matsushima T; Noda K; Shimizu Y; Fujiwara A; Takamatsu Y; Ichikawa Y; Nishimura H; Kinoshita M; Matsumoto S; Gatanaga H; Yoshimura K; Oka SI; Mikami A; Sugiura W; Sato T; Yoshida T; Shimada S; Mitsuya H
medRxiv; 2021 Jul; ():. PubMed ID: 34373860
[TBL] [Abstract][Full Text] [Related]
2. Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
Maeda K; Amano M; Uemura Y; Tsuchiya K; Matsushima T; Noda K; Shimizu Y; Fujiwara A; Takamatsu Y; Ichikawa Y; Nishimura H; Kinoshita M; Matsumoto S; Gatanaga H; Yoshimura K; Oka SI; Mikami A; Sugiura W; Sato T; Yoshida T; Shimada S; Mitsuya H
Sci Rep; 2021 Nov; 11(1):22848. PubMed ID: 34819514
[TBL] [Abstract][Full Text] [Related]
3. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
[TBL] [Abstract][Full Text] [Related]
4. Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants.
Padhiar NH; Liu JB; Wang X; Wang XL; Bodnar BH; Khan S; Wang P; Khan AI; Luo JJ; Hu WH; Ho WZ
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746466
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response.
Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
bioRxiv; 2022 Jun; ():. PubMed ID: 35702154
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
[TBL] [Abstract][Full Text] [Related]
10. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
[TBL] [Abstract][Full Text] [Related]
11. Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization.
Bonura F; De Grazia S; Bonura C; Sanfilippo GL; Giammanco GM; Amodio E; Ferraro D
J Appl Microbiol; 2022 May; 132(5):3987-3994. PubMed ID: 35083832
[TBL] [Abstract][Full Text] [Related]
12. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
Sariol CA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina A; Cruz L; Stone ET; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AK; Brien JD; Espino AM
medRxiv; 2021 Aug; ():. PubMed ID: 34100029
[TBL] [Abstract][Full Text] [Related]
13. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
14. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
15. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
16. Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
Kanji JN; Bailey A; Fenton J; Ling SH; Rivera R; Plitt S; Sligl WI; Taylor S; Turnbull L; Tipples G; Charlton CL
Vaccine; 2021 Sep; 39(39):5563-5570. PubMed ID: 34454782
[TBL] [Abstract][Full Text] [Related]
17. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.
Noori M; Nejadghaderi SA; Arshi S; Carson-Chahhoud K; Ansarin K; Kolahi AA; Safiri S
Rev Med Virol; 2022 Mar; 32(2):e2277. PubMed ID: 34286893
[TBL] [Abstract][Full Text] [Related]
18. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
19. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
20. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
